enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Analysts

enGene Holdings Inc. (NASDAQ:ENGNGet Free Report) has been given an average recommendation of “Buy” by the ten brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $25.22.

Several equities research analysts have recently issued reports on the company. Piper Sandler assumed coverage on enGene in a report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 target price on the stock. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. Morgan Stanley dropped their price objective on shares of enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Finally, UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and lowered their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th.

View Our Latest Report on ENGN

Hedge Funds Weigh In On enGene

Several hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. purchased a new stake in shares of enGene during the fourth quarter valued at $69,000. Jane Street Group LLC bought a new stake in enGene during the 4th quarter valued at about $93,000. Toronto Dominion Bank purchased a new stake in enGene in the 4th quarter valued at about $97,000. Cubist Systematic Strategies LLC grew its stake in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after acquiring an additional 2,080 shares in the last quarter. Finally, Corton Capital Inc. purchased a new position in shares of enGene during the fourth quarter worth approximately $157,000. Institutional investors own 64.16% of the company’s stock.

enGene Stock Up 0.9 %

NASDAQ ENGN opened at $5.40 on Friday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The stock’s 50 day moving average is $6.51 and its 200 day moving average is $7.12. The stock has a market cap of $275.28 million, a PE ratio of -9.31 and a beta of -0.61.

enGene (NASDAQ:ENGNGet Free Report) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Research analysts predict that enGene will post -1.56 EPS for the current fiscal year.

About enGene

(Get Free Report

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

Further Reading

Analyst Recommendations for enGene (NASDAQ:ENGN)

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.